Biofrontera AG

BFRA on NASDAQToday's ChangeVolume52 Week Range (Low/Hi)Market Cap
13.10US 0.05/0.38%1,10311.25 / 17.98291.52 M

Contact Information

Biofrontera AG

Headquarters:
Hemmelrather Weg 201,
Leverkusen, North Rhine-Westphalia
Germany, 51377
Tel: 49-214-87632-0
Email: Send a message
Website: Visit website
For more information...
Lead: Robert Thaemlitz

Biofrontera AG is an international biopharmaceutical company specializing in the development and commercialization of a platform of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin. Biofrontera's approved products focus on the treatment in the U.S. and Europe of actinic keratoses, which are skin lesions that can sometimes lead to skin cancer, as well as the treatment of certain forms of basal cell carcinoma in the European Union. American Depositary Shares representing Biofrontera's ordinary shares are listed on the NASDAQ Capital Market under the symbol "BFRA", and Biofrontera's ordinary shares are listed in the Frankfurt Stock Exchange (B8F, ISIN: DE0006046113). Information is also available at www.biofrontera.com.

Prof. Dr. Rer. Nat. Hermann Lübbert - Chief Executive Officer

Thomas Schaffer - Chief Financial Officer

Christoph Dünwald - Chief Compliance Officer

 

Ulrich Granzer, PhD. - Chairman

Jürgen Baumann - Independent Consultant

John Borer III, J.D. - Consultant

Reinhard Eyring - Consultant

Kevin Weber - Consultant

Hansjörg Plaggemars - Independent Consultant

Stock Information

Company Overview

Biofrontera AG is an international biopharmaceutical company specializing in the development and commercialization of a platform of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin. Biofrontera's approved products focus on the treatment in the U.S. and Europe of actinic keratoses, which are skin lesions that can sometimes lead to skin cancer, as well as the treatment of certain forms of basal cell carcinoma in the European Union. American Depositary Shares representing Biofrontera's ordinary shares are listed on the NASDAQ Capital Market under the symbol "BFRA", and Biofrontera's ordinary shares are listed in the Frankfurt Stock Exchange (B8F, ISIN: DE0006046113). Information is also available at www.biofrontera.com.

Management

Prof. Dr. Rer. Nat. Hermann Lübbert - Chief Executive Officer

Thomas Schaffer - Chief Financial Officer

Christoph Dünwald - Chief Compliance Officer

 

Board of Directors

Ulrich Granzer, PhD. - Chairman

Jürgen Baumann - Independent Consultant

John Borer III, J.D. - Consultant

Reinhard Eyring - Consultant

Kevin Weber - Consultant

Hansjörg Plaggemars - Independent Consultant

Contact Information

Headquarters:
Hemmelrather Weg 201,
Leverkusen, North Rhine-Westphalia
51377, Germany
Telephone: 49-214-87632-0
Email: Send a message
Website: Visit website